On February 8, 2022, Denovicon Therapeutics Founder & CEO, Scott Bembenek talked (along with BIOVIA’s Guy Oshiro) at SLAS 2022 about how AI and the use of virtual–real cycles is revolutionizing the drug discovery process.
Categories
Recent Posts
- Denovicon Reports Discovery of DNT-1569: A Highly Selective Small Molecule PARP7 Inhibitor for Immuno-Oncology
- Denovicon Introduces Quantum Physics-Driven Generative AI For Multi-Objective Optimization of Small-Molecule Drugs
- Denovicon Renewed for the 3DEXPERIENCE Lab Accelerator
- Denovicon Therapeutics Joins ARPA-H Investor Catalyst Hub Spoke Network
- Re-Inventing Drug Discovery